Lilly’s investigational triple hormone receptor agonist, retatrutide, has shown promising results in its first Phase 3 trial for type 2 diabetes, achieving significant reductions in both A1C levels and body weight. In the TRANSCEND-T2D-1 study, participants receiving the 12 mg dose experienced an average A1C reduction of 1.7% to 2.0% after 40 weeks, alongside an impressive average weight loss of 36.6 lbs (16.8%). Notably, the weight loss trajectory continued without plateauing throughout the trial, addressing a critical challenge in managing obesity among patients with type 2 diabetes.

These findings are particularly relevant as they highlight the dual benefits of retatrutide in managing glycemic control and weight loss, which are often difficult to achieve simultaneously in this patient population. Additionally, retatrutide demonstrated improvements in cardiovascular risk factors, including reductions in non-HDL cholesterol, triglycerides, and systolic blood pressure. The trial involved 537 participants and was designed to compare retatrutide’s efficacy against a placebo, providing a robust dataset that will contribute to understanding its potential impact on diabetes management and related metabolic disorders.

As the field of longevity science increasingly recognizes the interplay between metabolic health and aging, retatrutide’s development could pave the way for new therapeutic strategies that address not only diabetes but also associated conditions such as obesity and cardiovascular disease. The upcoming presentations at the American Diabetes Association Scientific Sessions and further results from ongoing trials will be critical in assessing retatrutide’s role in comprehensive healthspan improvement for individuals with metabolic dysfunction.

Source: investor.lilly.com